

=> d his

(FILE 'HOME' ENTERED AT 10:37:43 ON 20 SEP 2007)

FILE 'REGISTRY' ENTERED AT 10:37:53 ON 20 SEP 2007

L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM

FILE 'STNGUIDE' ENTERED AT 10:38:38 ON 20 SEP 2007

FILE 'REGISTRY' ENTERED AT 10:41:48 ON 20 SEP 2007

L3 STRUCTURE UPLOADED
L4 0 S L3 SSS SAM
L5 STRUCTURE UPLOADED
L6 STRUCTURE UPLOADED
L7 0 S L6 SSS SAM
L8 3 S L6 SSS FULL

FILE 'HCAPLUS' ENTERED AT 10:44:22 ON 20 SEP 2007

L9 1 S L8

FILE 'STNGUIDE' ENTERED AT 10:44:38 ON 20 SEP 2007


Uploading C:\Program Files\Stnexp\Queries\346allowance 2.str

L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6 STR



Structure attributes must be viewed using STN Express query preparation.

L9 1 L8

=> d 19 ibib abs hitstr

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:470326 HCAPLUS

DOCUMENT NUMBER: 141:38618

TITLE: Preparation of oxadiazolylchromones as modulators of tyrosine kinase signal transduction.

INVENTOR(S): Mujica-Fernaund, Teresa; Buchholz, Herwig; Carola, Christophe; Rautenberg, Wilfried; Sirrenberg, Christian

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: Eur. Pat. Appl., 33 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1426372	A1	20040609	EP 2003-26103	20031113
EP 1426372	B1	20060111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
DE 10256182	A1	20040624	DE 2002-10256182	20021202
AT 315564	T	20060215	AT 2003-26103	20031113
ES 2255654	T3	20060701	ES 2003-3026103	20031113
US 2004138464	A1	20040715	US 2003-725346	20031202
PRIORITY APPLN. INFO.:			DE 2002-10256182	A 20021202
OTHER SOURCE(S):	MARPAT 141:38618			

GI



I


- AB Title compds. [I; R = A, pyridyl, (substituted) Ph; X = H, OH, PhO, OA, O2CA, SO3H, OSO3H, OSO3A, halo, CO2H, CO2A, CONH2, NHSO2A, COA, CHO, SO2NH2, etc.; A = alkyl, fluoroalkyl; n = 1-4], were prepared Thus, 2,5-dihydroxyacetophenone and di-Et oxalate were heated 3 h at 80° in EtOH to give 6-hydroxy-2-ethoxycarbonylchromone. This was refluxed with aqueous HCl in HOAc to give 6-hydroxychromon-2-carboxylic acid. The latter in THF at -10° was treated with Et3N and iso-Bu chloroformate; after stirring for 1 h, 4-tert-butylbenzaloxime in THF was added followed by stirring for 30 min. at room temperature and at reflux for 90 min. to give 6-hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone. The latter inhibited Tie2 receptor tyrosine kinase with IC50 >10 µM.
- IT 700813-20-3P, 6-Hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone 700813-21-4P, 7-Hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone 700813-22-5P, 6-Hydroxy-2-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]chromone
- RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(claimed compound; preparation of oxadiazolylchromones as modulators of
tyrosine kinase signal transduction)


RN 700813-20-3 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-
5-yl]-6-hydroxy- (9CI) (CA INDEX NAME)




RN 700813-21-4 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-
5-yl]-7-hydroxy- (9CI) (CA INDEX NAME)



RN 700813-22-5 HCAPLUS

CN 4H-1-Benzopyran-4-one, 6-hydroxy-2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-
(9CI) (CA INDEX NAME)



FILE 'REGISTRY' ENTERED AT 10:47:37 ON 20 SEP 2007
L10 STRUCTURE UPLOADED
L11 17 S L10 SSS SAM
L12 294 S L10 SSS FULL

FILE 'HCAPLUS' ENTERED AT 10:49:35 ON 20 SEP 2007
L13 24 S L12


FILE 'STNGUIDE' ENTERED AT 10:50:11 ON 20 SEP 2007

L10 STRUCTURE UPLOADED

=> d l10

L10 HAS NO ANSWERS

L10 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l10 sss sam

SAMPLE SEARCH INITIATED 10:48:04 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 115 TO ITERATE

100.0% PROCESSED 115 ITERATIONS

17 ANSWERS

SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1657 TO 2943

PROJECTED ANSWERS: 93 TO 587

L11 17 SEA SSS SAM L10


=> d scan

L11 17 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1,2,4-Oxadiazole-5-carboxamide, N-butyl-3-(4-deoxy-4-fluoro- α -L-arabinopyranosyl)- (9CI)

MF C12 H18 F N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):17

FILE COVERS 1907 - 20 Sep 2007 VOL 147 ISS 13
 FILE LAST UPDATED: 19 Sep 2007 (20070919/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l12

L13 24 L12

=> d l13 ibib abs hitstr 1-24

L13 ANSWER 1 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:994273 HCAPLUS

DOCUMENT NUMBER: 146:8163

TITLE: In search of glycogen phosphorylase inhibitors:
 5-substituted 3-c- glucopyranosyl-1,2,4-oxadiazoles
 from β -D-glucopyranosyl cyanides upon cyclization
 of O-acylamidoxime intermediates

AUTHOR(S): Benlifa, Mahmoud; Vidal, Sebastien; Fenet, Bernard;
 Msaddek, Moncef; Goekjian, Peter G.; Praly,
 Jean-Pierre; Brunyanszki, Attila; Docsa, Tibor;
 Gergely, Pal

CORPORATE SOURCE: Lab. Chim. Org. 2, UMR-CNRS 5881, Univ. Claude Bernard
 Lyon 1, Villeurbanne, 69622, Fr.

SOURCE: European Journal of Organic Chemistry (2006), (18),
 4242-4256

CODEN: EJOCFK; ISSN: 1434-193X


PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:8163

GI



I



II

AB Substituted 5-(β -D-glucopyranosyl)-1,2,4-oxadiazoles such as I [R = H, MeCO, PhCH₂, PhCO; R₁ = Me, Ph, 4-MeOC₆H₄, 4-MeC₆H₄, 4-O₂NC₆H₄, 3-ClC₆H₄, 3-pyridinyl, 2-furyl, 2-thienyl, 1-naphthyl, 2-naphthyl, (E)- β -styryl] are prepared from β -D-glucopyranosyl cyanides II (R = PhCH₂, PhCO) by addition of hydroxylamine followed either by O-acylation of the intermediate amidoximes with acyl chlorides R₁COCl (R₁ = Me, Ph, 4-MeOC₆H₄, 4-MeC₆H₄, 4-O₂NC₆H₄, 3-ClC₆H₄, 3-pyridinyl, 2-furyl, 2-thienyl, 1-naphthyl, 2-naphthyl) and cyclocondensation or by one-pot cyclocondensation of benzyl-protected amidoximes with carboxylic acids R₁CO₂H [R₁ = Ph, 4-O₂NC₆H₄, 3-pyridinyl, 2-naphthyl, (E)- β -styryl]; I (R = H; R₁ = Me, Ph, 4-MeOC₆H₄, 4-MeC₆H₄, 4-O₂NC₆H₄, 3-ClC₆H₄, 3-pyridinyl, 2-furyl, 2-thienyl, 1-naphthyl, 2-naphthyl) and an amidoxime are tested for their inhibition of rabbit muscle glycogen phosphorylase b. Isolable O-acyl β -D-glucopyranosyl amidoximes are formed by the reaction of benzoyl-substituted β -D-glucopyranosyl amidoximes with acid chlorides R₁COCl (R₁ = Me, Ph, 4-MeOC₆H₄, 4-MeC₆H₄, 4-O₂NC₆H₄, 3-ClC₆H₄, 3-pyridinyl, 2-furyl, 2-thienyl, 1-naphthyl, 2-naphthyl). Eight of the twelve compds. tested as inhibitors of rabbit muscle glycogen

phosphorylase show no inhibition at concs. of 625 μ M; I (R = H; R1 = 2-naphthyl) inhibits rabbit muscle glycogen phosphorylase b with an IC50 value of < 300 μ M and a Ki value of 38.4 μ M.

IT 915313-74-5P 915313-75-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of β -D-glucopyranosyl oxadiazoles by addition of hydroxylamine to β -D-glucopyranosyl cyanides followed by O-acylation and cyclocondensation and their inhibition of rabbit muscle glycogen phosphorylase b)

RN 915313-74-5 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(2-thienyl)-1,2,4-oxadiazol-3-yl]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 915313-75-6 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(1-naphthalenyl)-1,2,4-oxadiazol-3-yl]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 915313-66-5P 915313-67-6P 915313-68-7P

915313-69-8P 915313-70-1P 915313-71-2P

915313-72-3P 915313-73-4P 915313-76-7P

915313-77-8P 915313-78-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation of β -D-glucopyranosyl oxadiazoles by addition of hydroxylamine to β -D-glucopyranosyl cyanides followed by O-acylation and cyclocondensation and their inhibition of rabbit muscle

glycogen phosphorylase b)

RN 915313-66-5 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-(5-methyl-1,2,4-oxadiazol-3-yl)-, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 915313-67-6 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-(5-phenyl-1,2,4-oxadiazol-3-yl)-, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 915313-68-7 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 915313-69-8 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 915313-70-1 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(4-nitrophenyl)-1,2,4-oxadiazol-3-yl]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 915313-71-2 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 915313-72-3 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(3-pyridinyl)-1,2,4-oxadiazol-3-yl]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 915313-73-4 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(2-furanyl)-1,2,4-oxadiazol-3-yl]-, (1S)-
(CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 915313-76-7 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(2-naphthalenyl)-1,2,4-oxadiazol-3-yl]-,
(1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 915313-77-8 HCAPLUS

CN D-Glucitol, 1-C-[5-[(1S)-1-amino-2-methylpropyl]-1,2,4-oxadiazol-3-yl]-1,5-anhydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 915313-78-9 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(2-deoxy-D-arabino-hex-1-enopyranosyl)-1,2,4-oxadiazol-3-yl]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 915313-52-9P 915313-53-0P 915313-54-1P

915313-55-2P 915313-56-3P 915313-57-4P

915313-58-5P 915313-59-6P 915313-60-9P

915313-61-0P 915313-62-1P 915313-63-2P

915313-64-3P 915313-65-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of β -D-glucopyranosyl oxadiazoles by addition of hydroxylamine to β -D-glucopyranosyl cyanides followed by O-acylation and cyclocondensation and their inhibition of rabbit muscle glycogen phosphorylase b)

RN 915313-52-9 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-(5-methyl-1,2,4-oxadiazol-3-yl)-, 2,3,4,6-tetrabenzoate, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 915313-53-0 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-(5-phenyl-1,2,4-oxadiazol-3-yl)-, 2,3,4,6-tetrabenzoate, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 915313-54-1 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4,6-tetrabenzoate, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 915313-55-2 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4,6-tetrabenzoate, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 915313-56-3 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(4-nitrophenyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4,6-tetrabenzoate, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 915313-57-4 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4,6-tetrabenzoate, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 915313-58-5 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(3-pyridinyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4,6-tetrabenzoate, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 915313-59-6 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(2-furanyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4,6-tetrabenzoate, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 915313-60-9 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(2-thienyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4,6-tetrabenzoate, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 915313-61-0 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(1-naphthalenyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4,6-tetrabenzoate, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 915313-62-1 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(2-naphthalenyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4,6-tetrabenzoate, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 915313-63-2 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-[(1S)-1-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2-methylpropyl]-1,2,4-oxadiazol-3-yl]-, 2,3,4,6-tetrabenzoate, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 915313-64-3 HCAPLUS

CN D-Glucitol, 1-C-[5-[(1S)-1-amino-2-methylpropyl]-1,2,4-oxadiazol-3-yl]-1,5-anhydro-, 2,3,4,6-tetrabenzoate, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 915313-65-4 HCAPLUS

CN D-Glucitol, C-anhydro-C-[5-[(1R)-2,3,4,6-tetra-O-benzoyl-D-glucitolyl]-1,2,4-oxadiazol-3-yl]-, 2-tetrabenzoate, [C(S)]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 915313-47-2P 915313-48-3P 915313-49-4P

915313-50-7P 915313-51-8P 915313-79-0P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of β -D-glucopyranosyl oxadiazoles by addition of hydroxylamine to β -D-glucopyranosyl cyanides followed by O-acylation and cyclocondensation and their inhibition of rabbit muscle glycogen phosphorylase b)

RN 915313-47-2 HCAPLUS

CN D-Glucitol, 1,5-anhydro-2,3,4,6-tetrakis-O-(phenylmethyl)-1-C-(5-phenyl-1,2,4-oxadiazol-3-yl)-, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 915313-48-3 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(4-nitrophenyl)-1,2,4-oxadiazol-3-yl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 915313-49-4 HCAPLUS

CN D-Glucitol, 1,5-anhydro-2,3,4,6-tetrakis-O-(phenylmethyl)-1-C-[5-(3-pyridinyl)-1,2,4-oxadiazol-3-yl]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 915313-50-7 HCAPLUS


CN D-Glucitol, 1,5-anhydro-1-C-[5-(2-naphthalenyl)-1,2,4-oxadiazol-3-yl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 915313-51-8 HCAPLUS
 CN D-Glucitol, 1,5-anhydro-1-C-[5-[(1E)-2-phenylethenyl]-1,2,4-oxadiazol-3-yl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



RN 915313-79-0 HCAPLUS
 CN D-Glucitol, 1,5-anhydro-1-C-[5-(1-naphthalenyl)-1,2,4-oxadiazol-3-yl]-2,3,4,6-tetraacetate, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:757596 HCAPLUS


DOCUMENT NUMBER: 145:315180
 TITLE: 1,3-Dipolar cycloaddition reactions on carbohydrate-based templates: Synthesis of spiro-isoxazolines and 1,2,4-oxadiazoles as glycogen phosphorylase inhibitors
 AUTHOR(S): Benlifa, Mahmoud; Vidal, Sebastien; Gueyrard, David; Goekjian, Peter G.; Msaddek, Moncef; Praly, Jean-Pierre
 CORPORATE SOURCE: Laboratoire de Chimie Organique 2 - Glycochimie, UMR-CNRS 5181, CPE-Lyon, Universite Claude Bernard Lyon 1, Villeurbanne, F-69622, Fr.
 SOURCE: Tetrahedron Letters (2006), 47(34), 6143-6147
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 145:315180
 AB 1,3-Dipolar cycloaddn. of aryl nitrile oxides to benzyl/acetyl-protected exo-glucals and to a benzoylated glucosyl cyanide led in high yield to spiro-isoxazolines and to 3-aryl-5-glucosyl-1,2,4-oxadiazoles, resp. The choice of the protective groups was important to the outcome of the cycloaddn. and for the deprotection of the adducts. Cleavage of the ester protecting groups (acetyl, benzoyl) provided water-soluble spiro-isoxazolines and 3-aryl-5-glucosyl-1,2,4-oxadiazoles, evaluated as glycogen phosphorylase inhibitors. Preliminary tests showed IC50 values in the μM range.
 IT 909109-15-5P 909109-16-6P 909109-17-7P
 RL: BYP (Byproduct); PREP (Preparation)
 (preparation of spiro-isoxazolines and oxadiazoles as glycogen phosphorylase inhibitors by dipolar cycloaddn. on carbohydrates)
 RN 909109-15-5 HCAPLUS
 CN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 909109-16-6 HCAPLUS
 CN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 909109-17-7 HCAPLUS

CN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 909109-13-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of spiro-isoxazolines and oxadiazoles as glycogen phosphorylase inhibitors by dipolar cycloaddn. on carbohydrates)

RN 909109-13-3 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 909109-09-7P 909109-10-0P 909109-11-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of spiro-isoxazolines and oxadiazoles as glycogen phosphorylase inhibitors by dipolar cycloaddn. on carbohydrates)

RN 909109-09-7 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-, 2,3,4,6-tetrabenzoate, (1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 909109-10-0 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)-, 2,3,4,6-tetrabenzoate, (1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 909109-11-1 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]-, 2,3,4,6-tetrabenzoate, (1R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 909109-12-2P 909109-14-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of spiro-isoxazolines and oxadiazoles as glycogen phosphorylase inhibitors by dipolar cycloaddn. on carbohydrates)

RN 909109-12-2 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-, (1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 909109-14-4 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:632773 HCAPLUS

DOCUMENT NUMBER: 145:103650

TITLE: Preparation of furopyridine and pyrrolopyridine derivatives and analogs thereof as G-protein coupled receptor agonists

INVENTOR(S): Fyfe, Matthew Colin Thor; Thomas, Gerard Hugh; Gardner, Lisa Sarah; Bradley, Stuart Edward; Gattrell, William; Rasamison, Chrystelle Marie; Shah, Vilasben Kanji

PATENT ASSIGNEE(S): Prosidion Ltd, UK

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006067532	A1	20060629	WO 2005-GB50265	20051223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,				

MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

GB 2004-28221

A 20041224



GB 2005-13256

A 20050630


OTHER SOURCE(S):

MARPAT 145:103650

GI



- AB Title compds. I [one of E1 and E2 = N and the other is N or CG1; G and G1 independently = H, halo, CF3, alkoxy, etc.; when dashed line is a double bond E = CR8 or N, when dashed line is a double bond E = CHR8, O or NR2; R2 = H or alkyl; R8 = H, OH, alkoxy or benzyloxy; T = O, S, NR2, (CH2)2, or E4=E5 wherein E4 and E5 independently = CH or N; B = bond, CH2=CH2 or (CH2)_j; j = 1-3; Q = bond, C(O)S or heteroaryl ring; A = (CH2)_n, wherein one CH2 group may be replace by O, S, CO, CHOH, etc.; n = 0-6; Z = substituted carbocycle or N-heterocycle], and their pharmaceutically acceptable salts or N-oxides thereof, are prepared and disclosed as agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes. Thus, e.g., II was prepared by reaction of furo[3,2-c]pyridine-2-carboxylic acid with 4-mercaptopiperidine-1-carboxylic acid tert-Bu ester. In cAMP assays, representative compds. of the invention were found to increase cAMP at an EC50 of less than 10 μM.
- IT 895126-12-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of furopyridine and pyrrolopyridine derivs. and analogs thereof as G-protein coupled receptor agonists)
- RN 895126-12-2 HCAPLUS
- CN 1-Piperidinecarboxylic acid, 4-[[5-[3-(phenylmethoxy)furo[3,2-c]pyridin-2-yl]-1,2,4-oxadiazol-3-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 895126-13-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of furopyridine and pyrrolopyridine derivs. and analogs thereof as G-protein coupled receptor agonists)

RN 895126-13-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-(3-hydroxyfuro[3,2-c]pyridin-2-yl)-1,2,4-oxadiazol-3-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:508651 HCAPLUS

DOCUMENT NUMBER: 146:163334

TITLE: Synthesis and Structural Analysis of Oxadiazole Carboxamide Deoxyribonucleoside Analogs. [Erratum to document cited in CA146:100959]

AUTHOR(S): Adelfinskaya, Olga; Wu, Weidong; Davisson, V. Jo; Bergstrom, Donald E.

CORPORATE SOURCE: Walther Cancer Institute, Indianapolis, IN, USA

SOURCE: Nucleosides, Nucleotides & Nucleic Acids (2006), 25(3), 352

CODEN: NNNAFY; ISSN: 1525-7770

PUBLISHER: Taylor & Francis, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The following name was omitted from the author list: Dr. Weidong Wu. The correct author list should read: "Olga Adelfinskaya, Weidong Wu, V. Jo Davisson, and Donald E. Bergstrom".

IT 869796-21-4P 869796-22-5P


RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(crystal structure; synthesis and structural anal. of oxadiazole carboxamide deoxyribonucleoside analogs (Erratum))

RN 869796-21-4 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-(2-deoxy-β-D-erythro-pentofuranosyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 869796-22-5 HCAPLUS

CN 1,2,4-Oxadiazole-3-carboxamide, 5-(2-deoxy- β -D-erythro-pentofuranosyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 917608-68-5P 917608-69-6P


RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and structural anal. of oxadiazole carboxamide deoxyribonucleoside analogs (Erratum))

RN 917608-68-5 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-[2-deoxy-5-O-[(hydroxy[(hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl)]- β -D-erythro-pentofuranosyl]-, ammonium salt (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 NH₃

RN 917608-69-6 HCAPLUS

CN 1,2,4-Oxadiazole-3-carboxamide, 5-[2-deoxy-5-O-[(hydroxy[(hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl)]- β -D-erythro-pentofuranosyl]-, ammonium salt (1:2) (CA INDEX NAME)


Absolute stereochemistry.



● 2 NH₃


IT 917608-62-9P 917608-63-0P 917608-64-1P
 917608-65-2P 917608-66-3P 917608-67-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (synthesis and structural anal. of oxadiazole carboxamide
 deoxyribonucleoside analogs (Erratum))
 RN 917608-62-9 HCAPLUS
 CN 1,2,4-Oxadiazole-5-carboxylic acid, 3-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-
 β-D-erythro-pentofuranosyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 917608-63-0 HCAPLUS
 CN 1,2,4-Oxadiazole-3-carboxylic acid, 5-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-
 β-D-erythro-pentofuranosyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 917608-64-1 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-[2-deoxy-5-O-[(4-methylphenyl)sulfonyl]- β -D-erythro-pentofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 917608-65-2 HCAPLUS

CN 1,2,4-Oxadiazole-3-carboxamide, 5-[2-deoxy-5-O-[(4-methylphenyl)sulfonyl]- β -D-erythro-pentofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 917608-66-3 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-[2-deoxy-5-O-[hydroxy (phosphonooxy) phosphinyl]- β -D-erythro-pentofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 917608-67-4 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-[2-deoxy-5-O-[hydroxy (phosphonooxy) phosphinyl]- β -D-erythro-pentofuranosyl]-, ammonium salt (1:1) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 5 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1327582 HCAPLUS

DOCUMENT NUMBER: 146:100959

TITLE: Synthesis and Structural Analysis of Oxadiazole Carboxamide Deoxyribonucleoside Analogs

AUTHOR(S): Adelfinskaya, Olga; Jo Davissan, V. Jo; Bergstrom, Donald E.

CORPORATE SOURCE: Walther Cancer Institute, Indianapolis, IN, USA

SOURCE: Nucleosides, Nucleotides & Nucleic Acids (2005), 24(10-12), 1919-1945

CODEN: MNNAFY; ISSN: 1525-7770

PUBLISHER: Taylor & Francis, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Two novel C-linked oxadiazole carboxamide nucleosides 5-(2'-deoxy-3',5'-β-D-erythro-pentofuranosyl)-1,2,4-oxadiazole-5-carboxamide (I) and 5-(2'-deoxy-3',5'-β-D-erythro-pentofuranosyl)-1,2,4-oxadiazole-3-carboxamide (II) were successfully synthesized and characterized by X-ray crystallog. The crystallog. anal. shows that both unnatural nucleoside analogs 1 and 2 adopt the C2'-endo ("south") conformation. The orientation of the oxadiazole carboxamide nucleobase moiety was determined as anti (conformer A) and high anti (conformer B) in the case of the nucleoside analog I whereas the syn conformation is adapted by the unnatural nucleoside II. Furthermore, nucleoside analogs I and II were converted with high efficiency to corresponding nucleoside triphosphates through the combination chemo-enzymic approach. Oxadiazole carboxamide deoxyribonucleoside analogs represent valuable tools to study DNA polymerase recognition, fidelity of nucleotide incorporation, and extension.

IT 869796-21-4P 869796-22-5P


RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(crystal structure; synthesis and structural anal. of oxadiazole carboxamide deoxyribonucleoside analogs)

RN 869796-21-4 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-(2-deoxy-β-D-erythro-pentofuranosyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 869796-22-5 HCAPLUS

CN 1,2,4-Oxadiazole-3-carboxamide, 5-(2-deoxy-β-D-erythro-pentofuranosyl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 917608-68-5P 917608-69-6P

RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and structural anal. of oxadiazole carboxamide deoxyribonucleoside analogs)

RN 917608-68-5 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-, ammonium salt (1:2) (CA INDEX NAME)


Absolute stereochemistry.

● 2 NH₃

RN 917608-69-6 HCAPLUS

CN 1,2,4-Oxadiazole-3-carboxamide, 5-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-, ammonium salt (1:2) (CA INDEX NAME)

Absolute stereochemistry.

● 2 NH₃

IT 917608-62-9P 917608-63-0P 917608-64-1P

917608-65-2P 917608-66-3P 917608-67-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and structural anal. of oxadiazole carboxamide deoxyribonucleoside analogs)

RN 917608-62-9 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxylic acid, 3-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- β -D-erythro-pentofuranosyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 917608-63-0 HCAPLUS

CN 1,2,4-Oxadiazole-3-carboxylic acid, 5-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- β -D-erythro-pentofuranosyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 917608-64-1 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-[2-deoxy-5-O-[(4-methylphenyl)sulfonyl]- β -D-erythro-pentofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 917608-65-2 HCAPLUS

CN 1,2,4-Oxadiazole-3-carboxamide, 5-[2-deoxy-5-O-[(4-methylphenyl)sulfonyl]- β -D-erythro-pentofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 917608-66-3 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-[2-deoxy-5-O-[hydroxy (phosphonooxy)phosphinyl]- β -D-erythro-pentofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 917608-67-4 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-[2-deoxy-5-O-[hydroxy (phosphonooxy)phosphinyl]- β -D-erythro-pentofuranosyl]-, ammonium salt (1:1) (CA INDEX NAME)

Absolute stereochemistry.

● NH₃

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1146758 HCAPLUS

DOCUMENT NUMBER: 144:2129

TITLE: Efficient Primer Strand Extension beyond Oxadiazole Carboxamide Nucleobases

AUTHOR(S): Adelfinskaya, Olga; Nashine, Vishal C.; Bergstrom, Donald E.; Davisson, V. Jo

CORPORATE SOURCE: Department of Medicinal Chemistry and Molecular

Pharmacology, Purdue University, West Lafayette, IN, 47907, USA

SOURCE: Journal of the American Chemical Society (2005), 127(46), 16000-16001
CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Two oxadiazole carboxamide deoxyribonucleoside analogs are described that can be incorporated and efficiently extended by Taq DNA polymerase. The primer strand extension beyond oxadiazole nucleoside analogs occurs at rates similar to the values observed for the canonical Watson-Crick base pairs irrespectively of the template nucleobase. These distinctive chemical effects in DNA polymerase extensions are attributed to the smaller size and unique electronic properties of the oxadiazole nucleobase.

IT 869796-23-6 869796-24-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(efficient primer strand extension beyond oxadiazole carboxamide nucleobases by Taq DNA polymerase)

RN 869796-23-6 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-(2-deoxy-5-O-phosphono-β-D-erythro-pentofuranosyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 869796-24-7 HCAPLUS

CN 1,2,4-Oxadiazole-3-carboxamide, 5-(2-deoxy-5-O-phosphono-β-D-erythro-pentofuranosyl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 869796-21-4 869796-22-5
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(oxadiazole carboxamide nucleobase analog; efficient primer strand extension beyond oxadiazole carboxamide nucleobases by Taq DNA polymerase)

RN 869796-21-4 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-(2-deoxy-β-D-erythro-pentofuranosyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 869796-22-5 HCAPLUS

CN 1,2,4-Oxadiazole-3-carboxamide, 5-(2-deoxy-β-D-erythro-pentofuranosyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:917078 HCAPLUS

DOCUMENT NUMBER: 142:249630

TITLE: 2-(3-Phenyl-1,2,4-oxadiazol-5-yl)-4H-1-benzopyran-3-ol

AUTHOR(S): Wang, Hai Bo; Chen, Jia Hui; Wang, Jin Tang

CORPORATE SOURCE: Department of Applied Chemistry, College of Science, Nanjing University of Technology, Nanjing, 210009, Peop. Rep. China

SOURCE: Acta Crystallographica, Section E: Structure Reports Online (2004), E60(11), o1917-o1918
CODEN: ACSEBH; ISSN: 1600-5368
URL: <http://journals.iucr.org/e/issues/2004/11/00/ya6223/index.html>

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English


AB The title compound was synthesized by the reaction of Me {2-[(3-phenyl-1,2,4-oxadiazol-5-yl)methoxy]phenyl}acetate and Na hydride. Crystals of the compound are monoclinic, space group P2₁/n, with a 5.675(1), b 9.346(2), c 25.440(5) Å, β 92.06(3)°; Z = 4, dc = 1.440; R = 0.043, R_w(F₂) = 0.176 for 2625 reflections. The mol. adopts the enol form, stabilized by an intramol. O-H...N H bond, which gives rise to a H-bonded six-membered pseudo-ring. All non-H atoms are coplanar within 0.13 Å.

IT 845523-27-5P, 2-(3-Phenyl-1,2,4-oxadiazol-5-yl)-4H-1-benzopyran-3-ol

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and crystal structure of)

RN 845523-27-5 HCAPLUS

CN 4H-1-Benzopyran-3-ol, 2-(3-phenyl-1,2,4-oxadiazol-5-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:470326 HCAPLUS

DOCUMENT NUMBER: 141:38618

TITLE: Preparation of oxadiazolylchromones as modulators of tyrosine kinase signal transduction.

INVENTOR(S): Mujica-Fernaund, Teresa; Buchholz, Herwig; Carola, Christophe; Rautenberg, Wilfried; Sirrenberg, Christian

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: Eur. Pat. Appl., 33 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1426372	A1	20040609	EP 2003-26103	20031113
EP 1426372	B1	20060111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
DE 10256182	A1	20040624	DE 2002-10256182	20021202
AT 315564	T	20060215	AT 2003-26103	20031113
ES 2255654	T3	20060701	ES 2003-3026103	20031113
US 2004138464	A1	20040715	US 2003-725346	20031202
PRIORITY APPLN. INFO.:			DE 2002-10256182	A 20021202

OTHER SOURCE(S): MARPAT 141:38618

GI



I

AB Title compds. [I; R = A, pyridyl, (substituted) Ph; X = H, OH, PhO, OA, O2CA, SO3H, OSO3H, OSO3A, halo, CO2H, CO2A, CONH2, NHSO2A, COA, CHO, SO2NH2, etc.; A = alkyl, fluoroalkyl; n = 1-4], were prepared Thus, 2,5-dihydroxyacetophenone and di-Et oxalate were heated 3 h at 80° in EtOH to give 6-hydroxy-2-ethoxycarbonylchromone. This was refluxed with aqueous HCl in HOAc to give 6-hydroxychromon-2-carboxylic acid. The latter in THF at -10° was treated with Et3N and iso-Bu chloroformate; after stirring for 1 h, 4-tert-butylbenzaloxime in THF was added followed by stirring for 30 min. at room temperature and at reflux for 90 min. to give 6-hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-

yl]chromone. The latter inhibited Tie2 receptor tyrosine kinase with IC50 >10 μ M.


IT 700813-20-3P, 6-Hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone 700813-21-4P, 7-Hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone 700813-22-5P, 6-Hydroxy-2-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]chromone

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of oxadiazolylchromones as modulators of tyrosine kinase signal transduction)


RN 700813-20-3 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]-6-hydroxy- (9CI) (CA INDEX NAME)




RN 700813-21-4 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]-7-hydroxy- (9CI) (CA INDEX NAME)



RN 700813-22-5 HCAPLUS

CN 4H-1-Benzopyran-4-one, 6-hydroxy-2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)



L13 ANSWER 9 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:204619 HCAPLUS

DOCUMENT NUMBER: 142:23214

TITLE: Product class 6: 1,2,4-oxadiazoles

AUTHOR(S): Hemming, K.

CORPORATE SOURCE: Dept. of Chemical and Biological Sciences, University of Huddersfield, Huddersfield, HD1 3DH, UK

SOURCE: Science of Synthesis (2004), 13, 127-184

CODEN: SSCYJ9

PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Methods for preparing 1,2,4-oxadiazoles are reviewed including cyclization, ring transformation, aromatization, substituent modification and solid phase synthesis.


IT 55428-64-3 55515-13-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of oxadiazoles via cyclization, ring transformation, aromatization, substituent modification and solid phase synthesis)


RN 55428-64-3 HCAPLUS

CN D-Ribitol, 1,4-anhydro-1-C-[(5S)-2,5-dihydro-5-methyl-1,2,4-oxadiazol-3-yl]-, 2,3,5-tribenzoate, (1S)- (9CI) (CA INDEX NAME)



RN 55515-13-4 HCAPLUS

CN D-Ribitol, 1,4-anhydro-1-C-[(5R)-2,5-dihydro-5-methyl-1,2,4-oxadiazol-3-yl]-, 2,3,5-tribenzoate, (1S)- (9CI) (CA INDEX NAME)



IT 55428-62-1P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of oxadiazoles via cyclization, ring transformation, aromatization, substituent modification and solid phase synthesis)

RN 55428-62-1 HCAPLUS

CN D-Ribitol, 1,4-anhydro-1-C-(5-methyl-1,2,4-oxadiazol-3-yl)-, 2,3,5-tribenzoate, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 205 THERE ARE 205 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L13 ANSWER 10 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:220605 HCAPLUS
 DOCUMENT NUMBER: 136:263385
 TITLE: Preparation of purine derivs. as adenosine A2a
 receptor agonists for pharmaceutical use as
 anti-inflammatory agents
 INVENTOR(S): Mantell, Simon John; Stephenson, Peter Thomas
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 161 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022630	A1	20020321	WO 2001-IB1612	20010903
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002072597	A1	20020613	US 2001-933421	20010820
US 6624158	B2	20030923		
CA 2422374	A1	20020321	CA 2001-2422374	20010903
CA 2422374	C	20070220		
AU 200184333	A	20020326	AU 2001-84333	20010903
EP 1317465	A1	20030611	EP 2001-963310	20010903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001014089	A	20030701	BR 2001-14089	20010903
JP 2004509130	T	20040325	JP 2002-526881	20010903
MX 2003PA02269	A	20030606	MX 2003-PA2269	20030314
PRIORITY APPLN. INFO.:			GB 2000-22695	A 20000915
			US 2000-239644P	P 20001012
			WO 2001-IB1612	W 20010903
OTHER SOURCE(S):			MARPAT 136:263385	
GI				



I



II

AB Purine derivs., such as I [R1 = H, alkyl, arylalkyl, etc.; R2 = alkylenylsulfonylaminomethyl; R19 = C-linked heteroaryl], were prepared for therapeutic use as anti-inflammatory agents which are adenosine A2a receptor agonists for treatment of conditions, such as bronchitis, inflammatory bowel disease and peripheral vascular disease. Thus, purine II was prepared via a multistep synthetic sequence starting from (3R,4R,5R)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-2,3,4-furantriol triacetate (ester), 2-methyl-1-propanesulfonyl chloride, 2,6-dichloropurine, and 2,2-diphenylethylamine. The prepared purine derivs. were tested for anti-inflammatory activity by their ability to inhibit neutrophil function which is indicative of A2a receptor agonist activity.

IT 404935-88-2P 404935-92-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of purine derivs. as adenosine A2a receptor agonists for pharmaceutical use as antiinflammatory agents)

RN 404935-88-2 HCAPLUS

CN 1-Propanesulfonamide, N-[[6-[(2,2-diphenylethyl)amino]-9-[(2R,3R,4S,5S)-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-dihydroxy-2-furanyl]-9H-purin-2-yl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 404935-92-8 HCAPLUS

CN 1-Propanesulfonamide, N-[[6-[(2,2-diphenylethyl)amino]-9-[(2R,3R,4S,5R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-3,4-dihydroxy-2-furanyl]-9H-purin-2-yl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 404936-00-1P 404936-02-3P 404936-04-5P
404936-09-0P 404936-24-9P 404936-25-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of purine derivs. as adenosine A2a receptor agonists for pharmaceutical use as antiinflammatory agents)

RN 404936-00-1 HCAPLUS

CN 1-Propanesulfonamide, N-[[9-[(2R,3R,4S,5S)-3,4-bis(acetyloxy)-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-2-yl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 404936-02-3 HCAPLUS

CN 1-Propanesulfonamide, N-[[9-[(2R,3R,4R,5R)-3,4-bis(benzoyloxy)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-2-yl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 404936-04-5 HCAPLUS

CN 1-Propanesulfonamide, N-[[9-[(2R,3R,4R,5R)-3,4-bis(acetyloxy)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-2-yl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 404936-09-0 HCAPLUS

CN 2,3,4-Furantriol, 5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, triacetate (ester), (3R,4R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 404936-24-9 HCAPLUS

CN 3,4-Furandiols, 2-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-5-methoxy-, (2R,3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 404936-25-0 HCAPLUS

CN 2,3,4-Furantriol, 5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-, triacetate (ester), (2S,3R,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:429503 HCAPLUS

DOCUMENT NUMBER: 133:193394

TITLE: Synthesis and antiviral activity of 3-(β-D-ribofuranosyl)-1,2,4-oxadiazole-5-carboxamide

AUTHOR(S): Pratap, Ram; Yarovenko, V. N.

CORPORATE SOURCE: Central Drug Research Institute, Lucknow, 226 001, India

SOURCE: Nucleosides, Nucleotides & Nucleic Acids (2000), 19(5 & 6), 845-849


CODEN: NNNAFY; ISSN: 1525-7770

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB The title compound was prepared by condensation reaction of amidoxime I with monoethyl oxaloyl chloride followed by reaction of the intermediate ribosyloxadiazolecarboxylate ester with methanolic NH₃. The compound 5 did not exhibit any significant activity against herpes simplex virus type-I (HSV-I) and semliki forest virus (SFV).

IT 289507-39-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(preparation and conversion to amide; synthesis and antiviral activity of 3-(β -D-ribofuranosyl)-1,2,4-oxadiazole-5-carboxamide)

RN 289507-39-7 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxylic acid, 3-(2,3,5-tri-O-benzoyl- β -D-ribofuranosyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 289507-38-6P


RL: SPN (Synthetic preparation); PREP (Preparation)

(synthesis and antiviral activity of 3-(β -D-ribofuranosyl)-1,2,4-oxadiazole-5-carboxamide)

RN 289507-38-6 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3- β -D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:819390 HCAPLUS

DOCUMENT NUMBER: 132:50209

TITLE: Preparation of 2-(purin-9-yl)-tetrahydrofuran-3,4-diol nucleosides as antiinflammatory agents

INVENTOR(S): Allen, David George; Chan, Chuen; Cook, Caroline Mary; Cousins, Richard Peter Charles; Cox, Brian; Dyke, Hazel Joan; Ellis, Frank; Geden, Joanna Victoria; Hobbs, Heather; Redgrave, Alison Judith; Swanson, Stephen; Bays, David

PATENT ASSIGNEE(S): Glaxo Group Ltd., UK; et al.

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 9967264 A1 19991229 WO 1999-EP4267 19990623
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2335758 A1 19991229 CA 1999-2335758 19990623
AU 9950281 A 20000110 AU 1999-50281 19990623
AU 758979 B2 20030403
BR 9911488 A 20010320 BR 1999-11488 19990623
EP 1090023 A1 20010411 EP 1999-934530 19990623
EP 1090023 B1 20030910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
TR 200100411 T2 20010723 TR 2001-200100411 19990623
HU 200102454 A2 20020128 HU 2001-2454 19990623
EE 200000764 A 20020415 EE 2000-764 19990623
JP 2002518511 T 20020625 JP 2000-555915 19990623
NZ 508918 A 20030328 NZ 1999-508918 19990623
AT 249474 T 20030915 AT 1999-934530 19990623
ZA 2000007515 A 20011214 ZA 2000-7515 20001214
IN 2000KN00644 A 20050311 IN 2000-KN644 20001218
NO 2000006521 A 20010222 NO 2000-6521 20001220
MX 2000PA12895 A 20010521 MX 2000-PA12895 20001220
HR 2000000895 A1 20011031 HR 2000-895 20001221
GB 1998-13565 A 19980623
WO 1999-EP4267 W 19990623
PRIORITY APPLN. INFO.:
OTHER SOURCE(S): MARPAT 132:50209
GI



AB Title nucleosides I (R1, R2 are selected independently from H, cycloalkyl, aralkyl, alkyl, aminoalkyl, H2NC(:NH)NH-alkyl, heterocycle; Z1-Z4 = together with the carbon form a 5-membered heterocyclic aromatic ring), were prepared as antiinflammatory agents. Thus, (2R,3R,4S,5R)-2-[6-(2,2-diphenylethylamino)-2-(2-pyrrolidin-1-yl-ethylamino)-purin-9-yl]-5-(5-methyl-4H-[1,2,4]triazol-3-yl)-tetrahydrofuran-3,4-diol formate was prepared as antiinflammatory agent and tested for its agonist activity against adenosine A2a, A3, A1 receptors (EC50 values as a ratio of that of NECA resp. 14.6, >1088, >8325).
IT 252761-04-9P 252761-05-0P 252761-06-1P
252761-07-2P 252761-09-4P 252761-10-7P

252761-12-9P 252761-13-0P 252761-15-2P

252761-16-3P 252761-42-5P 252761-43-6P


RL: BAC (Biological activity or effector, 'except adverse'); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(purin-9-yl)-tetrahydrofuran-3,4-diol nucleosides as antiinflammatory agents)

RN 252761-04-9 HCAPLUS

CN 3,4-Furandiol, 2-[2-[(trans-4-aminocyclohexyl)amino]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-, (2R,3R,4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252761-05-0 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5R)-2-[2-[(trans-4-aminocyclohexyl)amino]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 252761-04-9

CMF C33 H39 N9 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 252761-06-1 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-, (2R,3R,4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252761-07-2 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5R)-2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 252761-06-1

CMF C33 H36 N10 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 252761-09-4 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1-piperidiny)ethyl]amino]-9H-purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-, (2R,3R,4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252761-10-7 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5R)-2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1-piperidinyl)ethyl]amino]-9H-purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 252761-09-4

CMF C34 H41 N9 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 252761-12-9 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(4-morpholinyl)ethyl]amino]-9H-purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-, (2R,3R,4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252761-13-0 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5R)-2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(4-morpholinyl)ethyl]amino]-9H-purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 252761-12-9
 CMF C33 H39 N9 O5

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH


RN 252761-15-2 HCAPLUS
 CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]-9H-purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-, (2R,3R,4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252761-16-3 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5R)-2-[6-[(2,2-diphenylethyl)amino]-2-[[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]-9H-purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 252761-15-2
 CMF C36 H38 N8 O5

Absolute stereochemistry.




CM 2
 CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 252761-42-5 HCAPLUS
 CN Guanidine, [2-[[6-[(2,2-diphenylethyl)amino]-9-[(2R,3R,4S,5R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-3,4-dihydroxy-2-furanyl]-9H-purin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252761-43-6 HCAPLUS


CN Formic acid, compd. with [2-[[6-[(2,2-diphenylethyl)amino]-9-[(2R,3R,4S,5R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-3,4-dihydroxy-2-furanyl]-9H-purin-2-yl]amino]ethyl]guanidine (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 252761-42-5

CMF C30 H35 N11 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

IT 252760-59-1P 252760-71-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-(purin-9-yl)-tetrahydrofuran-3,4-diol nucleosides as antiinflammatory agents)

RN 252760-59-1 HCAPLUS

CN 3,4-Furandiol, 2-[2-chloro-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-, (2R,3R,4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252760-71-7 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5R)-2-[2-[(2-aminoethyl)amino]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)tetrahydro-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 252760-70-6

CMF C29 H33 N9 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 13 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:819388 HCAPLUS

DOCUMENT NUMBER: 132:64480

TITLE: Preparation of adenosine derivatives as antiinflammatory agents

INVENTOR(S): Bays, David Edmund; Cousins, Richard Peter Charles; Dyke, Hazel Joan; Eldred, Colin David; Judkins, Brian David; Pass, Martin; Pennell, Andrew Michael Kenneth

PATENT ASSIGNEE(S): Glaxo Group Ltd., UK

SOURCE: PCT Int. Appl., 161 pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9967262	A1	19991229	WO 1999-EP4182	19990621
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2335520	A1	19991229	CA 1999-2335520	19990621
CA 2335520	C	20070220		
AU 9945146	A	20000110	AU 1999-45146	19990621
AU 758018	B2	20030313		
BR 9911498	A	20010320	BR 1999-11498	19990621
EP 1090019	A1	20010411	EP 1999-927999	19990621
EP 1090019	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100449	T2	20010821	TR 2001-200100449	19990621
EE 200000784	A	20020415	EE 2000-784	19990621
EE 4853	B1	20070615		
HU 200102453	A2	20020429	HU 2001-2453	19990621
JP 2002518509	T	20020625	JP 2000-555913	19990621
JP 3378240	B2	20030217		
JP 2003040891	A	20030213	JP 2002-170486	19990621
NZ 508915	A	20030926	NZ 1999-508915	19990621
EP 1447407	A1	20040818	EP 2004-76465	19990621
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 277941	T	20041015	AT 1999-927999	19990621
PT 1090019	T	20050131	PT 1999-927999	19990621
ES 2226399	T3	20050316	ES 1999-927999	19990621
CN 1616459	A	20050518	CN 2004-10011939	19990621
TW 541312	B	20030711	TW 1999-88111178	19990701
ZA 2000007514	A	20020123	ZA 2000-7514	20001214
NO 2000006520	A	20010214	NO 2000-6520	20001220
NO 318788	B1	20050509		
MX 2000PA12915	A	20010521	MX 2000-PA12915	20001220
HR 2000000896	A1	20011231	HR 2000-896	20001221
HR 2000000896	B1	20060331		
BG 105155	A	20010928	BG 2001-105155	20010115
BG 65064	B1	20070131		
US 6492348	B1	20021210	US 2001-736018	20010306
HK 1034978	A1	20050408	HK 2001-105686	20010814
US 2003096788	A1	20030522	US 2002-217107	20020813
US 6677316	B2	20040113		
AU 2002323990	A1	20030403	AU 2002-323990	20021220
PRIORITY APPLN. INFO.:				
GB 1998-13554 A 19980623				
AU 1999-45146 A3 19990621				
EP 1999-927999 A3 19990621				
JP 2000-555913 A3 19990621				
WO 1999-EP4182 W 19990621				
US 2001-736018 A1 20010306				

OTHER SOURCE(S): MARPAT 132:64480
 GI



AB Adenosine derivs. I (X = O, CH₂; Y and Z = O, N, CH, alkylamine; W = heteroatom; R₁ = H, alkylcycloalkyl, heterocycle, fused bicyclic, substituted phenyl) which is an agonist at the adenosine A₁ and A₃ receptors. Thus, (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(tetrahydropyran-4-ylamino)-purin-9-yl]tetrahydrofuran-3,4-diol was prepared as adenosine A₁ and A₃ receptors (EC₅₀ are resp. 4.16 and 152).

IT 253124-52-6P 253124-53-7P 253124-54-8P
 253124-55-9P 253124-56-0P 253124-57-1P
 253124-58-2P 253124-59-3P 253124-66-2P
 253124-67-3P 253124-68-4P 253124-69-5P
 253124-70-8P 253124-71-9P 253124-72-0P
 253124-73-1P 253124-74-2P 253124-75-3P
 253124-76-4P 253124-77-5P 253124-78-6P
 253124-79-7P 253124-80-0P 253124-81-1P
 253124-82-2P 253124-83-3P 253124-84-4P
 253124-85-5P 253124-86-6P 253124-87-7P
 253124-88-8P 253124-89-9P 253124-90-2P
 253124-91-3P 253124-92-4P 253124-93-5P
 253124-94-6P 253124-95-7P 253124-96-8P
 253125-01-8P 253125-03-0P 253125-25-6P
 253125-26-7P 253125-50-7P 253125-56-3P
 253126-40-8P 253156-65-9P 253156-66-0P
 253156-68-2P 253156-69-3P 253156-71-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of adenosine derivs. as antiinflammatory agents)

RN 253124-52-6 HCAPLUS

CN 3,4-Furandiols, 2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)tetrahydro-5-[6-
 [(1S,2S)-2-hydroxycyclopentyl]amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-53-7 HCAPLUS

CN 3,4-Furandiyl, tetrahydro-2-(3-phenyl-1,2,4-oxadiazol-5-yl)-5-[6-
[(tetrahydro-2H-pyran-4-yl)amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry..



RN 253124-54-8 HCAPLUS

CN 3,4-Furandiyl, 2-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]tetrahydro-5-
[6-[[1S,2S)-2-hydroxycyclopentyl]amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-55-9 HCAPLUS

CN 3,4-Furandiol, 2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)tetrahydro-5-[6-
[(tetrahydro-2H-pyran-4-yl)amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 253124-56-0 HCAPLUS

CN 3,4-Furandiol, tetrahydro-2-[6-[(tetrahydro-2H-pyran-4-yl)amino]-9H-purin-
9-yl]-5-[3-(5-thiazolyl)-1,2,4-oxadiazol-5-yl]-, (2R,3R,4S,5S)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 253124-57-1 HCAPLUS

CN 3,4-Furandiol, tetrahydro-2-(3-methyl-1,2,4-oxadiazol-5-yl)-5-[6-
[(tetrahydro-2H-pyran-4-yl)amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 253124-58-2 HCAPLUS

CN 3,4-Furandiyl, 2-[6-[(3-fluoro-4-hydroxyphenyl)amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 253124-59-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[9-[(2R,3R,4S,5R)-5-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]tetrahydro-3,4-dihydroxy-2-furanyl]-9H-purin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-66-2 HCAPLUS

CN 3,4-Furandiol, 2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1,1-dimethylethyl)amino]-9H-purin-9-yl]tetrahydro-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-67-3 HCAPLUS

CN 3,4-Furandiol, 2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)tetrahydro-5-[6-[(1-methylethyl)amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-68-4 HCAPLUS

CN 3,4-Furandiol, tetrahydro-2-[6-[[[(1R,2R)-2-hydroxycyclopentyl]amino]-9H-purin-9-yl]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-69-5 HCAPLUS

CN 3,4-Furandiol, tetrahydro-2-(3-methyl-1,2,4-oxadiazol-5-yl)-5-[6-
[(tetrahydro-2H-thiopyran-4-yl)amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-70-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[9-[(2R,3R,4S,5S)-tetrahydro-3,4-dihydroxy-
5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-furanyl]-9H-purin-6-yl]amino]-, ethyl
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-71-9 HCAPLUS

CN 3,4-Furandiols, tetrahydro-2-(3-methyl-1,2,4-oxadiazol-5-yl)-5-[6-[(2-methylpropyl)amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-72-0 HCAPLUS

CN 3,4-Furandiols, 2-[6-((cyclopentylamino)-9H-purin-9-yl)]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-73-1 HCAPLUS

CN 3,4-Furandiols, 2-[6-[(cyclopropylmethyl)amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-74-2 HCAPLUS

CN 3,4-Furandiol, 2-[6-(cyclopropylamino)-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-75-3 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(2-fluorophenyl)amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-76-4 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(2,4-difluorophenyl)amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-77-5 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(cyclopropylmethyl)amino]-9H-purin-9-yl]-5-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-78-6 HCAPLUS

CN 3,4-Furandiol, 2-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]tetrahydro-5-[6-[(2-methylpropyl)amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-79-7 HCAPLUS

CN Ethanesulfonamide, 2-[[9-[(2R,3R,4S,5S)-5-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]tetrahydro-3,4-dihydroxy-2-furanyl]-9H-purin-6-yl]amino]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-80-0 HCAPLUS

CN 3,4-Furandiyl, 2-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]tetrahydro-5-[6-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-81-1 HCAPLUS

CN 3,4-Furandiyl, 2-[6-[(2-chloro-4-fluorophenyl)amino]-9H-purin-9-yl]-5-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-82-2 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(2,4-difluorophenyl)amino]-9H-purin-9-yl]-5-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-83-3 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(3,4-difluorophenyl)amino]-9H-purin-9-yl]-5-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-84-4 HCAPLUS

CN 3,4-Furandiol, 2-[6-(cyclopropylamino)-9H-purin-9-yl]tetrahydro-5-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-85-5 HCAPLUS

CN 3,4-Furandiol, tetrahydro-2-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-[6-[(2-methylpropyl)amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253124-86-6 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(cyclopropylmethyl)amino]-9H-purin-9-yl]tetrahydro-5-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

(NAME)


Absolute stereochemistry.



RN 253124-87-7 HCAPLUS

CN Ethanesulfonamide, N-methyl-2-[[9-[(2R,3R,4S,5S)-tetrahydro-3,4-dihydroxy-5-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-2-furanyl]-9H-purin-6-yl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-88-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(2,4-difluorophenyl)amino]-9H-purin-9-yl]tetrahydro-5-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-89-9 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(3,4-difluorophenyl)amino]-9H-purin-9-yl]tetrahydro-5-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-90-2 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(4-fluoro-2-methylphenyl)amino]-9H-purin-9-yl]tetrahydro-5-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-91-3 HCAPLUS

CN 3,4-Furandiol, 2-[3-(dimethylamino)-1,2,4-oxadiazol-5-yl]tetrahydro-5-[6-
[(tetrahydro-2H-pyran-4-yl)amino]-9H-purin-9-yl]-, (2S,3S,4R,5R) - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 253124-92-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[9-[(2R,3R,4S,5S)-5-(3-cyclopropyl-1,2,4-
oxadiazol-5-yl)tetrahydro-3,4-dihydroxy-2-furanyl]-9H-purin-6-yl]amino]-,
ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-93-5 HCAPLUS

CN 3,4-Furandiyl, 2-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]tetrahydro-5-[6-[(1-methylethyl)amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-94-6 HCAPLUS

CN 3,4-Furandiyl, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME).


Absolute stereochemistry.



RN 253124-95-7 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[9-[(2R,3R,4S,5S)-tetrahydro-3,4-dihydroxy-5-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-2-furanyl]-9H-purin-6-yl]amino]-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253124-96-8 HCAPLUS

CN Ethanesulfonamide, 2-[[9-[(2R,3R,4S,5S)-5-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-dihydroxy-2-furanyl]-9H-purin-6-yl]amino]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253125-01-8 HCAPLUS

CN Ethanesulfonamide, N-methyl-2-[[9-[(2R,3R,4S,5S)-tetrahydro-3,4-dihydroxy-5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-furanyl]-9H-purin-6-yl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253125-03-0 HCAPLUS

CN 3,4-Furandiol, tetrahydro-2-(3-methyl-1,2,4-oxadiazol-5-yl)-5-[6-[[[(1R)-1-methyl-2-phenylethyl]amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253125-25-6 HCAPLUS

CN 3,4-Furandiol, 2-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]tetrahydro-5-[6-[(tetrahydro-2H-pyran-4-yl)amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253125-26-7 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[9-[(2R,3R,4S,5S)-5-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]-2,3,4,5-tetrahydrofuran-2-yl]-9H-purin-9-yl]-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

1,2,4-oxadiazol-5-yl]tetrahydro-3,4-dihydroxy-2-furanyl]-9H-purin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253125-50-7 HCAPLUS

CN 3,4-Furandiol, 2-[6-(cyclopentylamino)-9H-purin-9-yl]tetrahydro-5-[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253125-56-3 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[2-chloro-6-[(1-ethylpropyl)amino]-9H-purin-9-yl]-5-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235414-68-3

CMF C19 H24 Cl N7 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 253126-40-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-(cyclopropylamino)-9H-purin-9-yl]-5-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253156-65-9 HCAPLUS

CN 3,4-Furandiol, 2-[6-(bicyclo[2.2.1]hept-2-ylamino)-9H-purin-9-yl]-5-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253156-66-0 HCAPLUS

CN 3,4-Furandiol, 2-[6-(bicyclo[2.2.1]hept-2-ylamino)-9H-purin-9-yl]tetrahydro-5-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253156-68-2 HCAPLUS

CN 3,4-Furandiol, 2-[6-(bicyclo[3.2.0]hept-6-ylamino)-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253156-69-3 HCAPLUS

CN 3,4-Furandiol, 2-[6-(bicyclo[2.2.1]hept-2-ylamino)-9H-purin-9-

yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 253156-71-7 HCAPLUS

CN 3,4-Furandiol, 2-[6-(bicyclo[2.2.1]hept-2-ylamino)-9H-purin-9-yl]-5-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




IT 253126-63-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of adenosine derivs. as antiinflammatory agents)

RN 253126-63-5 HCAPLUS

CN 3,4-Furandiol, 2-(6-chloro-9H-purin-9-yl)-5-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 14 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:529161 HCAPLUS

DOCUMENT NUMBER: 131:144794

TITLE: Preparation of 2-(purin-9-yl)-tetrahydrofuran-3,4-diol nucleosides as antiinflammatory agents

INVENTOR(S): Chan, Chuen; Cook, Caroline Mary; Cox, Brian; Cousins, Richard Peter Charles; Dyke, Hazel Joan; Ellis, Frank; Geden, Joanna Victoria; Swanson, Stephen; Bays, David

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9941267	A1	19990819	WO 1999-EP915	19990212
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2319009	A1	19990819	CA 1999-2319009	19990212
AU 9926235	A	19990830	AU 1999-26235	19990212
AU 757156	B2	20030206		
ZA 9901154	A	20000814	ZA 1999-1154	19990212
BR 9907886	A	20001017	BR 1999-7886	19990212
TR 200002355	T2	20001121	TR 2000-200002355	19990212
EP 1056759	A1	20001206	EP 1999-906229	19990212
EP 1056759	B1	20020904		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 200000358	A	20011015	EE 2000-358	19990212
HU 200100702	A2	20020128	HU 2001-702	19990212
JP 2002503669	T	20020205	JP 2000-531459	19990212
NZ 505812	A	20020301	NZ 1999-505812	19990212
AT 223429	T	20020915	AT 1999-906229	19990212
PT 1056759	T	20030131	PT 1999-906229	19990212
ES 2183516	T3	20030316	ES 1999-906229	19990212
IN 2000KN00189	A	20050311	IN 2000-KN189	20000803
MX 2000PA07793	A	20010613	MX 2000-PA7793	20000809
NO 2000004045	A	20000811	NO 2000-4045	20000811


HR 2000000538
 US 6610665
 HK 1032062
 PRIORITY APPLN. INFO.:

A1 20001231
 B1 20030826
 A1 20030620

HR 2000-538
 US 2000-622313
 HK 2001-102563
 GB 1998-3169
 GB 1998-13533
 WO 1999-EP915

20000811
 20000829
 20010410
 A 19980214
 A 19980623
 W 19990212

OTHER SOURCE(S): MARPAT 131:144794
 GI



AB Title nucleosides I (R1, R2 are selected independently from cycloalkyl, aralkyl, alkyl, aminoalkyl, haloalkyl, aryl; R3 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, hydroxyalkyl, haloalkyl, ester, amide, keto), were prepared as antiinflammatory agents. Thus, (2R,3R,4S,5S)-2-{6-(2,2-diphenyl-ethylamino)-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-tetrahydro-furan-3,4-diol bis(trifluoroacetate) was prepared as antiinflammatory agent and tested for its agonist activity against adenosine A2a, A3, A1 receptors (EC50 values as a ratio of that of NECA resp. 1.19, >197, 1306).

IT 235414-83-2P 235414-84-3P 235414-85-4P
 235414-86-5P 235414-87-6P 235414-88-7P
 235414-89-8P 235414-90-1P 235414-91-2P
 235414-92-3P 235414-93-4P 235414-94-5P
 235414-95-6P 235414-96-7P 235414-97-8P
 235414-98-9P 235414-99-0P 235415-00-6P
 235415-01-7P 235415-02-8P 235415-03-9P
 235415-04-0P 235415-05-1P 235415-06-2P
 235415-07-3P 235415-08-4P 235415-09-5P
 235415-10-8P 235415-11-9P 235415-12-0P
 235415-13-1P 235415-14-2P 235415-15-3P
 235415-16-4P 235415-17-5P 235415-18-6P
 235415-19-7P 235415-20-0P 235415-21-1P
 235415-22-2P 235415-23-3P 235415-24-4P
 235415-25-5P 235415-26-6P 235415-27-7P
 235415-28-8P 235415-29-9P 235415-30-2P
 235415-31-3P 235415-32-4P 235415-33-5P
 235415-34-6P 235415-35-7P 235415-36-8P
 235415-37-9P 235415-38-0P 235415-39-1P
 235415-40-4P 235415-41-5P 235415-42-6P
 235415-43-7P 235415-44-8P 235415-45-9P
 235415-46-0P 235415-47-1P 235415-48-2P

235415-49-3P 235415-50-6P 235415-51-7P
 235415-52-8P 235415-53-9P 235415-54-0P
 235415-55-1P 235415-56-2P 235415-57-3P
 235415-58-4P 235415-59-5P 235415-60-8P
 235415-61-9P 235415-62-0P 235415-63-1P
 235415-64-2P 235415-65-3P 235415-66-4P
 235415-67-5P 235415-68-6P 235415-69-7P
 235415-70-0P 235416-73-6P 235416-74-7P
 235416-76-9P 235416-78-1P 235416-79-2P
 235416-81-6P 235437-71-5P 235437-73-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(purin-9-yl)-tetrahydrofuran-3,4-diol nucleosides as antiinflammatory agents)

RN 235414-83-2 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235414-84-3 HCAPLUS


CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 235414-83-2


CMF C32 H34 N10 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 235414-85-4 HCAPLUS
CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235414-86-5 HCAPLUS
CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 235414-85-4
CMF C33 H36 N10 O4

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 235414-87-6 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[(3R)-3-pyrrolidinylamino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235414-88-7 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(2,2-diphenylethyl)amino]-2-[(3R)-3-pyrrolidinylamino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235414-87-6

CMF C31 H35 N9 O4


Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2



RN 235414-89-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[[(1S)-1-(hydroxymethyl)-2-methylpropyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235414-90-1 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(2,2-diphenylethyl)amino]-2-[[[(1S)-1-(hydroxymethyl)-2-methylpropyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235414-89-8

CMF C32 H38 N8 O5

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235414-91-2 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(1-ethylpropyl)amino]-2-[[2-(4-morpholinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235414-92-3 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(1-ethylpropyl)amino]-2-[[2-(4-morpholinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235414-91-2

CMF C23 H35 N9 O5

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235414-93-4 HCAPLUS

CN 3,4-Furandiol, 2-[6-amino-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235414-94-5 HCAPLUS
 CN 3,4-Furandiyl, 2-[6-amino-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 235414-93-4
 CMF C18 H22 N10 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 235414-95-6 HCAPLUS
 CN 3,4-Furandiyl, 2-[6-amino-2-[[2-(2-pyridinyl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235414-96-7 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-amino-2-[[2-(2-pyridinyl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235414-95-6

CMF C20 H23 N9 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235414-97-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-amino-2-[[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235414-98-9 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-amino-2-[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235414-97-8
 CMF C22 H26 N8 O5

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235414-99-0 HCAPLUS
 CN 3,4-Furandiol, 2-[6-amino-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-00-6 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-amino-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235414-99-0
 CMF C19 H24 N10 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-01-7 HCAPLUS
 CN 3,4-Furandiol, 2-[6-amino-2-(cyclopentylamino)-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-02-8 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-amino-2-(cyclopentylamino)-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-01-7
 CMF C17 H22 N8 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-03-9 HCAPLUS
 CN 3,4-Furandiol, 2-[6-amino-2-[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-04-0 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-amino-2-[[1S]-1-(hydroxymethyl)-2-phenylethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-03-9
 CMF C21 H24 N8 O5

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-05-1 HCAPLUS
 CN 3,4-Furandiol, 2-(3-ethyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]tetrahydro-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235415-06-2 HCAPLUS


CN Formic acid, compd. with (2S,3S,4R,5R)-2-(3-ethyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-05-1

CMF C24 H34 N10 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235415-07-3 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(1-ethylpropyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-(2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235415-08-4 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(1-ethylpropyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-07-3

CMF C23 H32 N10 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235415-09-5 HCAPLUS

CN 3,4-Furandiol, 2-[6-amino-2-[(2-phenylethyl)amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-10-8 HCAPLUS
 CN 3,4-Furandiol, 2-[6-amino-2-[(2-phenylethyl)amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 235415-09-5
 CMF C20 H22 N8 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 235415-11-9 HCAPLUS
 CN 3,4-Furandiol, 2-[6-[(1-ethylpropyl)amino]-2-[[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-12-0 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(1-ethylpropyl)amino]-2-[[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-11-9
 CMF C26 H34 N8 O5

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-13-1 HCAPLUS
 CN 3,4-Furandiol, 2-[6-[(1-ethylpropyl)amino]-2-[[2-(1-piperidiny)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-14-2 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(1-ethylpropyl)amino]-2-[[2-(1-piperidinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-13-1
 CMF C24 H37 N9 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-15-3 HCAPLUS
 CN 3,4-Furandiol, 2-(3-ethyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(4-morpholinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-16-4 HCAPLUS
 CN Formic acid, compd. with (2S,3S,4R,5R)-2-(3-ethyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(4-morpholinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-15-3
 CMF C24 H37 N9 O5

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-17-5 HCAPLUS
 CN 3,4-Furandiol, 2-(3-ethyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(1-piperidiny)ethyl]amino]-9H-purin-9-yl]tetrahydro-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-18-6 HCAPLUS
 CN Formic acid, compd. with (2S,3S,4R,5R)-2-(3-ethyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(1-piperidinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-17-5
 CMF C25 H39 N9 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-19-7 HCAPLUS
 CN 3,4-Furandiol, 2-(3-ethyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(2-pyridinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235415-20-0 HCAPLUS


CN Formic acid, compd. with (2S,3S,4R,5R)-2-(3-ethyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(2-pyridinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-19-7

CMF C25 H33 N9 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235415-21-1 HCAPLUS

CN 3,4-Furandiol, 2-[2-(cyclopentylamino)-6-[(1-ethylpropyl)amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 235415-22-2 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[2-(cyclopentylamino)-6-[(1-ethylpropyl)amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-21-1

CMF C22 H32 N8 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235415-23-3 HCAPLUS

CN 3,4-Furandiol, 2-[2-(cyclopentylamino)-6-[(1-ethylpropyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-24-4 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[2-(cyclopentylamino)-6-[(1-ethylpropyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-23-3
 CMF C23 H34 N8 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-25-5 HCAPLUS
 CN 3,4-Furandiol, 2-[6-[(1-ethylpropyl)amino]-2-[[[(1S,2S)-2-hydroxycyclopentyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-26-6 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(1-ethylpropyl)amino]-2-[[[(1S,2S)-2-hydroxycyclopentyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3,4-furandiyl (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-25-5
 CMF C22 H32 N8 O5

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-27-7 HCAPLUS
 CN 3,4-Furandiyl, 2-(3-ethyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[[(1S,2S)-2-hydroxycyclopentyl]amino]-9H-purin-9-yl]tetrahydro-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235415-28-8 HCAPLUS


CN Formic acid, compd. with (2S,3S,4R,5R)-2-(3-ethyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[[(1S,2S)-2-hydroxycyclopentyl]amino]-9H-purin-9-yl]]tetrahydro-3,4-furandiols (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-27-7

CMF C23 H34 N8 O5

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235415-29-9 HCAPLUS

CN 3,4-Furandiols, 2-[6-[(1-ethylpropyl)amino]-2-[(3R)-3-pyrrolidinylamino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-30-2 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(1-ethylpropyl)amino]-2-[(3R)-3-pyrrolidinylamino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-29-9
 CMF C21 H31 N9 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-31-3 HCAPLUS
 CN 3,4-Furandiol, 2-(3-ethyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[(3R)-3-pyrrolidinylamino]-9H-purin-9-yl]tetrahydro-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-32-4 HCAPLUS
 CN Formic acid, compd. with (2S,3S,4R,5R)-2-(3-ethyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[(3R)-3-pyrrolidinylamino]-9H-purin-9-yl]tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-31-3
 CMF C22 H33 N9 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-33-5 HCAPLUS
 CN 3,4-Furandiol, 2-[6-[(1-ethylpropyl)amino]-2-[[1S]-1-(hydroxymethyl)-2-methylpropyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235415-34-6 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(1-ethylpropyl)amino]-2-[[[(1S)-1-(hydroxymethyl)-2-methylpropyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-33-5

CMF C22 H34 N8 O5

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235415-35-7 HCAPLUS

CN 3,4-Furandiol, 2-[6-amino-2-[[2-(2-pyridinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235415-36-8 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-amino-2-[[2-(2-pyridinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-35-7

CMF C19 H21 N9 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235415-37-9 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(4-morpholinyl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235415-38-0 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(4-morpholinyl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-37-9

CMF C33 H39 N9 O5

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235415-39-1 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1-piperidinyl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-40-4 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1-piperidinyl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-39-1
 CMF C34 H41 N9 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-41-5 HCAPLUS
 CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-propyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-42-6 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-propyl-1,2,4-oxadiazol-5-yl)-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-41-5
 CMF C34 H38 N10 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-43-7 HCAPLUS
 CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-44-8 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3,4-furandiyl (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-43-7
 CMF C31 H32 N10 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-45-9 HCAPLUS
 CN 3,4-Furandiyl, 2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(1-piperidinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-46-0 HCAPLUS
 CN Formic acid, compd. with (2S,3S,4R,5R)-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(1-piperidinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-45-9
 CMF C26 H39 N9 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-47-1 HCAPLUS
 CN 3,4-Furandiol, 2:2(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(4-morpholinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-48-2 HCAPLUS
 CN Formic acid, compd. with (2S,3S,4R,5R)-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(4-morpholinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-47-1
 CMF C25 H37 N9 O5

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-49-3 HCAPLUS
 CN 3,4-Furandiol, 2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(2-pyridinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235415-50-6 HCAPLUS


CN Formic acid, compd. with (2S,3S,4R,5R)-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(2-pyridinyl)ethyl]amino]-9H-purin-9-yl]tetrahydro-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-49-3

CMF C26 H33 N9 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235415-51-7 HCAPLUS

CN 3,4-Furandiol, 2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]tetrahydro-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-52-8 HCAPLUS
 CN Formic acid, compd. with (2S,3S,4R,5R)-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[6-[(1-ethylpropyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]tetrahydro-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-51-7
 CMF C25 H34 N10 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-53-9 HCAPLUS
 CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1-pyrrolidinyl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-54-0 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(1-pyrrolidinyl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-53-9
 CMF C33 H39 N9 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-55-1 HCAPLUS
 CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(2-pyridinyl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235415-56-2 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(2,2-diphenylethyl)amino]-2-[[2-(2-pyridinyl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-55-1

CMF C34 H35 N9 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235415-57-3 HCAPLUS

CN 3,4-Furandiol, 2-[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-58-4 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-57-3
 CMF C37 H40 N8 O6

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-59-5 HCAPLUS
 CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[(2-hydroxyethyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235415-60-8 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(2,2-diphenylethyl)amino]-2-[(2-hydroxyethyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-59-5

CMF C29 H32 N8 O5

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235415-61-9 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[(4-fluorophenyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235415-62-0 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(2,2-diphenylethyl)amino]-2-[(4-fluorophenyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-61-9

CMF C33 H31 F N8 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235415-63-1 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(2,2-diphenylethyl)amino]-2-[[[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-64-2 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(2,2-diphenylethyl)amino]-2-[[[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-63-1
 CMF C38 H41 N9 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-65-3 HCAPLUS
 CN 3,4-Furandiol, 2-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-5-[2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-6-[(2-phenylethyl)amino]-9H-purin-9-yl]-, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235415-66-4 HCAPLUS
 CN Formic acid, compd. with (2S,3S,4R,5R)-2-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-5-[2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-6-[(2-phenylethyl)amino]-9H-purin-9-yl]-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-65-3
 CMF C27 H32 N10 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 235415-67-5 HCAPLUS
 CN 3,4-Furandiol, 2-[6-[(2-cyclohexylethyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235415-68-6 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[6-[(2-cyclohexylethyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-67-5

CMF C27 H38 N10 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2


O=CH-OH

RN 235415-69-7 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(3,3-dimethylbutyl)amino]-2-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-

yl)tetrahydro-, (2R,3R,4S,5S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235415-70-0 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S) - 2 - [6 - [(3,3-dimethylbutyl)amino] - 2 - [[2 - (1-methyl-1H-imidazol-4-yl)ethyl]amino] - 9H-purin-9-yl] - 5 - (3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235415-69-7

CMF C25 H36 N10 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235416-73-6 HCAPLUS

CN 3,4-Furandiol, 2 - [2 - [(trans-4-aminocyclohexyl)amino] - 6 - [(1-ethylpropyl)amino] - 9H-purin-9-yl] - 5 - (3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235416-74-7 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[2-[(trans-4-aminocyclohexyl)amino]-6-[(1-ethylpropyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235416-73-6

CMF C24 H37 N9 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 235416-76-9 HCAPLUS

CN 3,4-Furandiol, 2-[2-[(trans-4-aminocyclohexyl)amino]-6-[(1-ethylpropyl)amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235416-78-1 HCAPLUS

CN 3,4-Furandiol, 2-[2-[(trans-4-aminocyclohexyl)amino]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235416-79-2 HCAPLUS


CN Formic acid, compd. with (2R,3R,4S,5S)-2-[2-[(trans-4-aminocyclohexyl)amino]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235416-78-1

CMF C33 H39 N9 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 235416-81-6 HCAPLUS
CN Formic acid, compd. with (2R,3R,4S,5S)-2-[2-[(trans-4-aminocyclohexyl)amino]-6-[(1-ethylpropyl)amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235416-76-9
CMF C23 H35 N9 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 235437-71-5 HCAPLUS
CN 3,4-Furandiol, 2-[2-[(2-bicyclo[2.2.1]hept-2-ylethyl)amino]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235437-73-7 HCAPLUS
 CN Formic acid, compd. with (2R,3R,4S,5S)-2-[2-[(2-bicyclo[2.2.1]hept-2-ylethyl)amino]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-3,4-furandiol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235437-71-5
 CMF C36 H42 N8 O4

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

IT 235414-46-7P 235414-52-5P 235414-55-8P
 235414-58-1P 235414-59-2P 235414-64-9P
 235414-66-1P 235414-68-3P 235414-79-6P
 235414-80-9P 235414-81-0P 235414-82-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 2-(purin-9-yl)-tetrahydrofuran-3,4-diol nucleosides as antiinflammatory agents)
 RN 235414-46-7 HCAPLUS
 CN 3,4-Furandiol, 2-[2-chloro-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235414-52-5 HCAPLUS

CN 3,4-Furandiol, 2-[2-chloro-6-[(1-ethylpropyl)amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235414-55-8 HCAPLUS

CN 3,4-Furandiol, 2-[2-chloro-6-[(1-ethylpropyl)amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235414-58-1 HCAPLUS

CN 3,4-Furandiol, 2-(6-amino-2-chloro-9H-purin-9-yl)tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 235414-59-2 HCAPLUS

CN 3,4-Furandiol, 2-(6-amino-2-chloro-9H-purin-9-yl)-5-(3-ethyl-1,2,4-

oxadiazol-5-yl)tetrahydro-, diacetate (ester), (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235414-64-9 HCAPLUS

CN 3,4-Furandiolside, 2-[2-chloro-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]tetrahydro-5-(3-propyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235414-66-1 HCAPLUS

CN 3,4-Furandiolside, 2-[2-chloro-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]tetrahydro-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235414-68-3 HCAPLUS

CN 3,4-Furandiolside, 2-[2-chloro-6-[(1-ethylpropyl)amino]-9H-purin-9-yl]-5-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235414-79-6 HCAPLUS

CN 3,4-Furandiol, 2-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-5-methoxy-, diacetate (ester), (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235414-80-9 HCAPLUS

CN 3,4-Furandiol, 2-(2,6-dichloro-9H-purin-9-yl)-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, diacetate (ester), (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 235414-81-0 HCAPLUS


CN 3,4-Furandiol, 2-[6-azido-2-[[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]-9H-purin-9-yl]]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, 3,4-diacetate, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235414-82-1 HCAPLUS
 CN 3,4-Furandiol, 2-[6-amino-2-[[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]-9H-purin-9-yl]-5-(3-ethyl-1,2,4-oxadiazol-5-yl)tetrahydro-, 3,4-diacetate, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 15 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:663421 HCAPLUS

DOCUMENT NUMBER: 129:343649

TITLE: Reaction of 2-tert-butyl-3-phenyloxaziridine with alkyl isothiocyanates and its application to glucosylaminoheterocycle synthesis

AUTHOR(S): Shimizu, Masao; Gama, Yasuo; Shibuya, Isao

CORPORATE SOURCE: National Institute of Materials and Chemical Research, Tsukuba, 305-8565, Japan

SOURCE: Heterocycles (1998), 48(9), 1935-1941

CODEN: HTCYAM; ISSN: 0385-5414

PUBLISHER: Japan Institute of Heterocyclic Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 2-Tert-Butyl-3-phenyloxaziridine was heated with alkyl isothiocyanates to afford 4-alkyl-2-tert-butyl-3-phenyl-1,2,4-oxadiazolidine-5-thiones. The reaction mechanism of the ring formation was discussed. This reaction was applicable to synthesis of glucosylaminoheterocycles.

IT 215365-94-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(reaction of butylphenyloxaziridine with alkyl isothiocyanates and its application to glucosylaminoheterocycle synthesis)

RN 215365-94-9 HCAPLUS

CN 1,2,4-Oxadiazolidine-5-thione, 2-(1,1-dimethylethyl)-3-phenyl-4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 215365-95-0P 215365-96-1P 215365-97-2P


RL: SPN (Synthetic preparation); PREP (Preparation)

(reaction of butylphenyloxaziridine with alkyl isothiocyanates and its application to glucosylaminoheterocycle synthesis)

RN 215365-95-0 HCAPLUS

CN 1,2,4-Oxadiazolidine-5-thione, 2-(1,1-dimethylethyl)-3-phenyl-4-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 215365-96-1 HCAPLUS

CN 1,2,4-Oxadiazolidine-5-thione, 2-(1,1-dimethylethyl)-3-phenyl-4-(2,3,4,6-tetra-O-benzoyl- β -D-glucopyranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 215365-97-2 HCAPLUS

CN 1,2,4-Oxadiazolidine-5-thione, 2-(1,1-dimethylethyl)-4-β-D-glucopyranosyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 16 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:466481 HCAPLUS

DOCUMENT NUMBER: 125:196130

TITLE: Synthesis of fluorinated C-nucleosides. Synthesis of N-alkyl 3-(4'-deoxy-4'-fluoro-β-L-arabinopyranosyl)-1,2,4-oxadiazole-5-carboxamides

AUTHOR(S): Cheng, Hua; Ma, Lingtai; Zhang, Lihe

CORPORATE SOURCE: Sch. of Pharmaceutical Sciences, Beijing Medical Univ., 100083, Peop. Rep. China


SOURCE: Gaodeng Xuexiao Huaxue Xuebao (1996), 17(7), 1078-1082
CODEN: KTHPDM; ISSN: 0251-0790

PUBLISHER: Gaodeng Jiaoyu Chubanshe

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

GI




AB Title compds. I (R = MeNH, PrNH, BuNH, cyclohexylamino, piperidino, morpholino) were synthesized starting from D-xylose via fluorination of the corresponding N-alkyl 3- β -D-xylopyranosyl-1,2,4-oxadiazole-5-carboxamides with diethylaminosulfur trifluoride. The configuration and conformation of these new C-nucleoside derivs. were identified by ¹H NMR, ¹³C NMR, ¹⁹F NMR, ¹H-¹H COSY and MS.

IT 180677-56-9P 180677-57-0P 180677-58-1P
180677-59-2P 180677-60-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of (deoxyfluoroarabinopyranosyl)oxadiazolecarboxamides)

RN 180677-56-9 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxylic acid, 3-(2,3,4-tri-O-benzoyl- β -D-xylopyranosyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180677-57-0 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, N-propyl-3- β -D-xylopyranosyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 180677-58-1 HCAPLUS


CN 1,2,4-Oxadiazole-5-carboxamide, N-methyl-3- β -D-xylopyranosyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 180677-59-2 HCAPLUS
 CN 1,2,4-Oxadiazole-5-carboxamide, N-butyl-3-β-D-xylopyranosyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 180677-60-5 HCAPLUS
 CN 1,2,4-Oxadiazole-5-carboxamide, N-cyclohexyl-3-β-D-xylopyranosyl-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 180677-61-6P 180677-62-7P 180677-63-8P
 180677-64-9P 180677-65-0P 180677-66-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of (deoxyfluoroarabinopyranosyl)oxadiazolecarboxamides)
 RN 180677-61-6 HCAPLUS
 CN Morpholine, 4-[(3-β-D-xylopyranosyl-1,2,4-oxadiazol-5-yl)carbonyl]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180677-62-7 HCAPLUS

CN Piperidine, 1-[(3-β-D-xylopyranosyl-1,2,4-oxadiazol-5-yl)carbonyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180677-63-8 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-(4-deoxy-4-fluoro-α-L-arabinopyranosyl)-N-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180677-64-9 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, 3-(4-deoxy-4-fluoro-α-L-arabinopyranosyl)-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180677-65-0 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, N-butyl-3-(4-deoxy-4-fluoro- α -L-arabinopyranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180677-66-1 HCAPLUS

CN 1,2,4-Oxadiazole-5-carboxamide, N-cyclohexyl-3-(4-deoxy-4-fluoro- α -L-arabinopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 17 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:746726 HCAPLUS

DOCUMENT NUMBER: 123:340720

TITLE: The Squalestatins: Synthesis and Biological Activity of Some C3-Modified Analogs; Replacement of a Carboxylic Acid or Methyl Ester with an Isoelectronic Heterocyclic Functionality

AUTHOR(S): Bamford, Mark J.; Chan, Chuen; Craven, Andrew P.; Dymock, Brian W.; Green, Darren; Henson, Richard A.; Kirk, Barrie E.; Lester, Michael G.; Procopiu, Panayiotis A.; et al.


CORPORATE SOURCE: Medicines Research Centre, Glaxo Research and Development Ltd., Stevenage/Hertfordshire, SG1 2NY, UK
SOURCE: Journal of Medicinal Chemistry (1995), 38(18), 3502-13
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

GI



- AB A series of squalestatsins, e.g. I (R = CO₂H, CO₂Me, R₂-R₄, Z = H, R₁), modified at the C3-position with a heterocyclic functionality was prepared and evaluated in vitro as inhibitors of squalene synthase (SQS). Structure-activity relationships for compds. with the 4,6-dimethyloctenoate at C6-(S1 analogs) were different from those for analogs lacking the C6 ester (H1 analogs), with a greater dependence on the nature of the C3-substituent for the H1 series. Potent SQS inhibitory activity equivalent to that of H1 is retained by a C3-(tetrazol-5-yl) analog, i.e., a carboxylic acid mimetic. The C3-Me ester derivative is 10-fold less active than H1, and SQS inhibitory activity similar to that of the Me ester was retained only in those C3-heterocycle-substituted H1 analogs for which electrostatic potential maps of the C3-substituent were closely similar to that of a Me ester.
- IT 170641-41-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of squalestatsins as squalene synthase inhibitors)
- RN 170641-41-5 HCAPLUS
- CN L-erythro-L-talo-6-Dodeculo-6,3-furanose, 1,6-anhydro-2,3-di-C-carboxy-7,8,9,11,12-pentadeoxy-9-methylene-1-C-(3-methyl-1,2,4-oxadiazol-5-yl)-11-(phenylmethyl)-, 10-acetate 4-(4,6-dimethyl-2-octenoate), [1S,4(2E,4S,6S),6S]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 170641-42-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of squalestatins as squalene synthase inhibitors)

RN 170641-42-6 HCAPLUS

CN L-erythro-L-talo-6-Dodeculo-6,3-furanose, 1,6-anhydro-2,3-di-C-carboxy-7,8,9,11,12-pentadeoxy-9-methylene-1-C-(3-methyl-1,2,4-oxadiazol-5-yl)-11-(phenylmethyl)-, 10-acetate, (1S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 170641-36-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of squalestatins as squalene synthase inhibitors)

RN 170641-36-8 HCAPLUS

CN L-erythro-L-talo-6-Dodeculo-6,3-furanose, 1,6-anhydro-7,8,9,11,12-pentadeoxy-2,3-bis-C-(methoxycarbonyl)-9-methylene-1-C-(3-methyl-1,2,4-oxadiazol-5-yl)-11-(phenylmethyl)-, 10-acetate 4-(4,6-dimethyl-2-octenoate), [1S,4(2E,4S,6S),6S]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L13 ANSWER 18 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:60016 HCAPLUS


DOCUMENT NUMBER: 118:60016

TITLE: Synthesis of C-nucleosides - synthesis of 3-β-D-xylopyranosyl-1,2,4-oxadiazoles


AUTHOR(S): Dong, Lingjiao; Li, Li; Ma, Lingtai; Zhang, Lihe

CORPORATE SOURCE: Sch. Pharm. Sci., Beijing Med. Univ., Beijing, 100083,


SOURCE: Peop. Rep. China
 Gaodeng Xuexiao Huaxue Xuebao (1992), 13(5), 617-22
 CODEN: KTHPDM; ISSN: 0251-0790
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese
 OTHER SOURCE(S): CASREACT 118:60016
 GI



AB Fourteen new derivs. of 3- β -D-xylopyranosyl-1,2,4-oxadiazole were synthesized in good yields via condensation of protected β -D-xylopyranosyl amidoxime with anhydrides or various substituted benzoyl chlorides. The 1,2,4-oxadiazole ring was formed directly by condensation of xylopyranosyl amidoxime and various anhydrides, but if the condensation occurred by using substituted benzoyl chloride instead of anhydride, the cyclization was completed by two steps. The mechanism was discussed. Title compds. e.g., I is stable under the condition of 1 mol/L HCl, 1 mol/L NaOH or at high temperature
 IT 145240-64-8P 145240-65-9P 145240-66-0P
 145240-67-1P 145240-68-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deprotection of)
 RN 145240-64-8 HCAPLUS
 CN D-Xylitol, 1,5-anhydro-1-C-(5-methyl-1,2,4-oxadiazol-3-yl)-, 2,3,4-tribenzoate, (1S)- (9CI) (CA INDEX NAME)




RN 145240-65-9 HCAPLUS
 CN D-Xylitol, 1,5-anhydro-1-C-(5-ethyl-1,2,4-oxadiazol-3-yl)-, 2,3,4-tribenzoate, (1S)- (9CI) (CA INDEX NAME)




RN 145240-66-0 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4-tribenzoate, (1S)- (9CI) (CA INDEX NAME)




RN 145240-67-1 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-(5-phenyl-1,2,4-oxadiazol-3-yl)-, 2,3,4-tribenzoate, (1S)- (9CI) (CA INDEX NAME)



RN 145240-68-2 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-[5-(4-nitrophenyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4-tribenzoate, (1S)- (9CI) (CA INDEX NAME)




IT 145240-70-6P 145240-71-7P 145240-72-8P

145240-73-9P 145300-06-7P 145300-07-8P


145300-08-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 145240-70-6 HCAPLUS


CN D-Xylitol, 1,5-anhydro-1-C-(5-methyl-1,2,4-oxadiazol-3-yl)-, (1S)- (9CI)
(CA INDEX NAME)

RN 145240-71-7 HCAPLUS


CN D-Xylitol, 1,5-anhydro-1-C-(5-ethyl-1,2,4-oxadiazol-3-yl)-, (1S)- (9CI)
(CA INDEX NAME)

RN 145240-72-8 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-, (1S)- (9CI) (CA INDEX NAME)




RN 145240-73-9 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-(5-phenyl-1,2,4-oxadiazol-3-yl)-, (1S)- (9CI)
(CA INDEX NAME)


RN 145300-06-7 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4-tribenzoate, (1S)- (9CI) (CA INDEX NAME)




RN 145300-07-8 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-[5-(4-nitrophenyl)-1,2,4-oxadiazol-3-yl]-, (1S)- (9CI) (CA INDEX NAME)



RN 145300-08-9 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]-, (1S)- (9CI) (CA INDEX NAME)



L13 ANSWER 19 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:39322 HCAPLUS

DOCUMENT NUMBER: 118:39322

TITLE: Synthesis of derivatives of 3-β-D-xylopyranosyl-1,2,4-oxadiazoles

AUTHOR(S): Dong, Lingjiao; Li, Li; Ma, Lingtai; Zhang, Lihe

CORPORATE SOURCE: Sch. Pharm. Sci., Beijing Med. Univ., Beijing, 100083, Peop. Rep. China

SOURCE: Chinese Chemical Letters (1992), 3(8), 597-600


CODEN: CCLEE7; ISSN: 1001-8417

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 118:39322

GI




AB Xylopyranosyl oxadiazoles, e.g. I (R = Me, Et, Ph, CF₃), were prepared via cyclocondensation of protected β-D-xylopyranosyl amidoxime II with acid anhydrides or various substituted benzoyl chlorides in good yield. The stability of 1,2,4-oxadiazole ring and mechanism of cyclization were investigated.

IT 145240-64-8P 145240-65-9P 145240-66-0P
145240-67-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debenzylation of)


RN 145240-64-8 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-(5-methyl-1,2,4-oxadiazol-3-yl)-, 2,3,4-tribenzoate, (1S)- (9CI) (CA INDEX NAME)




RN 145240-65-9 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-(5-ethyl-1,2,4-oxadiazol-3-yl)-, 2,3,4-tribenzoate, (1S)- (9CI) (CA INDEX NAME)




RN 145240-66-0 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4-tribenzoate, (1S)- (9CI) (CA INDEX NAME)



RN 145240-67-1 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-(5-phenyl-1,2,4-oxadiazol-3-yl)-, 2,3,4-tribenzoate, (1S)- (9CI) (CA INDEX NAME)




IT 145240-68-2P 145240-69-3P 145240-70-6P

145240-71-7P 145240-72-8P 145240-73-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 145240-68-2 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-[5-(4-nitrophenyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4-tribenzoate, (1S)- (9CI) (CA INDEX NAME)



RN 145240-69-3 HCAPLUS


CN D-Xylitol, 1,5-anhydro-1-C-[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]-, 2,3,4-tribenzoate, (1S)- (9CI) (CA INDEX NAME)




RN 145240-70-6 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-(5-methyl-1,2,4-oxadiazol-3-yl)-, (1S)- (9CI)

(CA INDEX NAME)




RN 145240-71-7 HCAPLUS


CN D-Xylitol, 1,5-anhydro-1-C-(5-ethyl-1,2,4-oxadiazol-3-yl)-, (1S)- (9CI)
(CA INDEX NAME)

RN 145240-72-8 HCAPLUS


CN D-Xylitol, 1,5-anhydro-1-C-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-, (1S)- (9CI) (CA INDEX NAME)



RN 145240-73-9 HCAPLUS

CN D-Xylitol, 1,5-anhydro-1-C-(5-phenyl-1,2,4-oxadiazol-3-yl)-, (1S)- (9CI)
(CA INDEX NAME)


L13 ANSWER 20 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1986:443242 HCAPLUS
 DOCUMENT NUMBER: 105:43242
 TITLE: Synthesis of 5-(β -D-ribofuranosyl)-1,2,4-oxadiazole-3-carboxamide
 AUTHOR(S): Hennen, William J.; Robins, Roland K.
 CORPORATE SOURCE: Cancer Res. Cent., Brigham Young Univ., Provo, UT, 84602, USA
 SOURCE: Journal of Heterocyclic Chemistry (1985), 22(6), 1747-8
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 105:43242
 GI



AB The title compound (I) was prepared in three steps from ethoxycarbonylformamide oxime and anhydroallonyl chloride II in 62% overall yield. An acid catalyzed deesterification was required to prevent a facile base catalyzed elimination reaction. I gave 46% inhibition of leukemia L1210 and 43% inhibition of leukemia P388 at 1×10^{-4} M in cell culture. I also showed a virus rating of 0.38 and 0.51 against vaccinia and HSV-2 viral lines, resp. with very little cellular toxicity.

IT 103082-72-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and ammonolysis of)
 RN 103082-72-0 HCAPLUS
 CN 1,2,4-Oxadiazole-3-carboxylic acid, 5- β -D-ribofuranosyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 103082-73-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antileukemia and antiviral activity of)
 RN 103082-73-1 HCAPLUS

CN 1,2,4-Oxadiazole-3-carboxamide, 5- β -D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 103082-68-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and attempted deprotection of, with methanolic ammonia, elimination reaction in)

RN 103082-68-4 HCAPLUS

CN 1,2,4-Oxadiazole-3-carboxylic acid, 5-(2,3,5-tri-O-benzoyl- β -D-ribofuranosyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 103082-69-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and deacetylation of)

RN 103082-69-5 HCAPLUS

CN 1,2,4-Oxadiazole-3-carboxylic acid, 5-(2,3,5-tri-O-acetyl- β -D-ribofuranosyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 103082-71-9P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 103082-71-9 HCAPLUS

CN 1,2,4-Oxadiazole-3-carboxamide, 5-(2-deoxy-D-erythro-1-pentenofuranosyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 21 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1981:525911 HCAPLUS
 DOCUMENT NUMBER: 95:125911
 TITLE: Synthesis and biological activity of certain derivatives of oxazinomycin and related oxadiazole nucleosides
 AUTHOR(S): Srivastava, Prem C.; Robins, Roland K.
 CORPORATE SOURCE: Cancer Res. Cent., Brigham Young Univ., Provo, UT, 84602, USA
 SOURCE: Journal of Medicinal Chemistry (1981), 24(10), 1172-7
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Seven title compds. were synthesized and tested for antitumor activity against L1210 and P388 leukemia cells and for activity against a variety of bacteria and fungi. None of the compds. was active in any of the described tests. Three oxadiazoles were also tested for antiviral activity in vitro against herpes simplex virus (HSV) type 1 and 2 and parainfluenza virus type 3. 2-beta-D-Ribofuranosyl-1,2,4-oxadiazole-3,5-dione (I) [78828-90-7] had significant activity against HSV type 1, but was less active than either ribavirin or acyclovir.

IT 78828-86-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deacetylation of)


RN 78828-86-1 HCAPLUS
 CN 1,2,4-Oxadiazolidine-3,5-dione, 2-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 78828-88-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and deprotection of)
 RN 78828-88-3 HCAPLUS
 CN 1,2,4-Oxadiazolidine-3,5-dione, 2-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-
 β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 78828-89-4P 78828-90-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and neoplasm inhibition and virucidal activity of)
 RN 78828-89-4 HCAPLUS
 CN 1,2,4-Oxadiazolidine-3,5-dione, 2-(2-deoxy-β-D-erythro-
 pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 78828-90-7 HCAPLUS
 CN 1,2,4-Oxadiazolidine-3,5-dione, 2-β-D-ribofuranosyl- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




L13 ANSWER 22 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1980:198696 HCAPLUS
 Correction of: 1979:23572
 DOCUMENT NUMBER: 92:198696
 Correction of: 90:23572
 TITLE: 3-(2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl)-5-trichloromethyl-1,2,4-oxadiazole. An improved synthesis of 2,5-anhydro-3,4,6-tri-O-benzoyl-D-allonamidoxime, a versatile intermediate
 AUTHOR(S): Revankar, Ganapathi R.; Robins, Roland K.
 CORPORATE SOURCE: Nucleic Acid Res. Inst., ICN Pharm., Inc., Irvine, CA, 92715, USA
 SOURCE: Nucleic Acid Chem. (1978), Volume 1, 465-8.
 Editor(s): Townsend, Leroy B.; Tipson, R. Stuart.
 Wiley: New York, N. Y.
 CODEN: 39GCA6
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 GI




AB Reaction of 2,3,5-tri-O-benzoyl-β-D-ribofuranosyl cyanide with H2NOH in H2O-EtOH at reflux gave 85.3% allonamidoxime I, which on cyclization with Cl3CCOCl gave 91.2% oxadiazole II.
 IT 68682-44-0P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 68682-44-0 HCAPLUS
 CN D-Ribitol, 1,4-anhydro-1-C-[5-(trichloromethyl)-1,2,4-oxadiazol-3-yl]-, 2,3,5-tribenzoate, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L13 ANSWER 23 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1979:23572 HCAPLUS
 DOCUMENT NUMBER: 90:23572
 TITLE: 3-(2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl)-5-trichloromethyl-1,2,4-oxadiazole: An improved synthesis of 2,5-anhydro-3,4,6-tri-O-benzoyl-D-allonamidoxime, a versatile intermediate
 AUTHOR(S): Revankar, Ganapathi R.; Robins, Roland K.
 CORPORATE SOURCE: Nucleic Acid Res. Inst., ICN Pharm., Inc., Irvine, CA, USA
 SOURCE: Nucleic Acid Chem. (1978), Volume 1, 465-8.
 Editor(s): Townsend, Leroy B.; Tipson, R. Stuart.
 Wiley: New York, N. Y.
 CODEN: 39GCA6
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 GI



AB 2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl cyanide was refluxed 1 h with H₂NOH in EtOH-H₂O to give 85.3% anhydroallonamidoxime I, which was cyclized with Cl₃CCOCl in C₆H₆ containing pyridine at reflux and the product was chromatographed on silica gel column to give 91.2% oxadiazole nucleoside II.
 IT 68682-44-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 68682-44-0 HCAPLUS
 CN D-Ribitol, 1,4-anhydro-1-C-[5-(trichloromethyl)-1,2,4-oxadiazol-3-yl]-, 2,3,5-tribenzoate, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 24 OF 24 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1975:531863 HCAPLUS

DOCUMENT NUMBER: 83:131863

TITLE: C-Glycosyl nucleosides. VII. Synthesis of some 3-β-D-ribofuranosyl-1,2,4-oxadiazoles and 3-β-D-ribofuranosylpyrazoles

AUTHOR(S): Repke, David B.; Albrecht, Hans P.; Moffatt, John G.

CORPORATE SOURCE: Inst. Mol. Biol., Syntex Res., Palo Alto, CA, USA

SOURCE: Journal of Organic Chemistry (1975), 40(17), 2481-7

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 2,5-Anhydro-3,4,6-tri-O-benzoyl-D-allonamidoxime (I) was prepared via either addition of NH₂OH to 2,3,5-tri-O-benzoyl-β-D-ribofuranosyl cyanide or chlorination and amination of 2,5-anhydro-3,4,6-tri-O-benzoyl-D-allose oxime. Reactions of I with Ac₂O and Et acetoacetate gave 5-substituted 3-β-D-ribofuranosyl-1,2,4-oxadiazoles, while MeCHO gave Δ²-1,2,4-oxadiazoline. The condensation of both O-benzoyl and O-benzyl derivs. of 2,5-anhydro-D-allose with 1-chloroacetylidenetriphenylphosphorane gave unsatd. chloro ketones that can be cyclized with N₂H₄ to 5-methyl-3-β-D-ribofuranosylpyrazoles. A potential route for the synthesis of pyrazoles is explored via addition of Et glyoxylate hydrazone to nitroolefins followed by chlorination and base-catalyzed cyclization. This has required the synthesis of a C-glycosyl nitroolefin via addition of MeNO₂ to 2,5-anhydro-3,4,6-tri-O-benzyl-D-allose followed by dehydration. While pyrazole synthesis was achieved in a model system, the carbohydrate derivative failed to cyclize.

IT 55428-62-1P 55428-63-2P 55428-64-3P


55428-65-4P 55515-13-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 55428-62-1 HCAPLUS

CN D-Ribitol, 1,4-anhydro-1-C-(5-methyl-1,2,4-oxadiazol-3-yl)-, 2,3,5-tribenzoate, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 55428-63-2 HCAPLUS


CN D-Ribitol, 1,4-anhydro-1-C-(5-methyl-1,2,4-oxadiazol-3-yl)-, (S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry..



RN 55428-64-3 HCAPLUS


CN D-Ribitol, 1,4-anhydro-1-C-[(5S)-2,5-dihydro-5-methyl-1,2,4-oxadiazol-3-yl]-, 2,3,5-tribenzoate, (1S)- (9CI) (CA INDEX NAME)



RN 55428-65-4 HCAPLUS


CN 2-Propanone, 1-[3-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 55515-13-4 HCAPLUS

CN D-Ribitol, 1,4-anhydro-1-C-[(5R)-2,5-dihydro-5-methyl-1,2,4-oxadiazol-3-yl]-, 2,3,5-tribenzoate, (1S)- (9CI) (CA INDEX NAME)




L10 STRUCTURE UPLOADED

=> d l10

L10 HAS NO ANSWERS

L10 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l10 sss sam

SAMPLE SEARCH INITIATED 10:48:04 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 115 TO ITERATE

100.0% PROCESSED 115 ITERATIONS

17 ANSWERS

SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1657 TO 2943

PROJECTED ANSWERS: 93 TO 587

L11 17 SEA SSS SAM L10